Evidence map›Paper›PMID 42647402›Full record

ArticleChemMedChem2026

Design and Synthesis of Combretastatin A4-Chalcone Hybrids as Tubulin Polymerization Inhibitors.

Chetna Jadala, Srinivasa Reddy Telukutla, Ganga Reddy Velma, Sowmya Dastari, Ramya Tokala, Lakshmi Tulasi Naraharisetti, Chandraiah Godugu, Suresh K Bhargava, Magdalena Plebanski, Nagula Shankaraiah and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chetna JadalaDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.ORCID https://orcid.org/0000-0003-0318-5445
Srinivasa Reddy TelukutlaCentre for Advanced Materials & Industrial Chemistry (CAMIC), School of Science, RMIT University, Melbourne, Australia.
Ganga Reddy VelmaCentre for Advanced Materials & Industrial Chemistry (CAMIC), School of Science, RMIT University, Melbourne, Australia.ORCID https://orcid.org/0000-0001-5054-2519
Sowmya DastariDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Ramya TokalaDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Lakshmi Tulasi NaraharisettiNational Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Chandraiah GoduguNational Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Suresh K BhargavaCentre for Advanced Materials & Industrial Chemistry (CAMIC), School of Science, RMIT University, Melbourne, Australia.ORCID https://orcid.org/0000-0002-9298-5112
Magdalena PlebanskiAccelerator for Translational Research in Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, STEM College, RMIT University, Victoria, Australia.ORCID https://orcid.org/0000-0001-6889-3667
Nagula ShankaraiahDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Ahmed KamalDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.ORCID https://orcid.org/0000-0002-4107-1775

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new series of combretastatin A4-chalcone hybrids were designed and synthesized to explore their potential as cytotoxic agents. The compounds were evaluated for cytotoxic activity, tubulin inhibition, and anti-angiogenic properties. The designed hybrids exhibited significant cytotoxic effects across all the tested cancer cell lines. Among them, two compounds, 5d and 5o, exhibited potent cytotoxicity, with IC

Indexed as

Antineoplastic AgentsChalconeDrug DesignStilbenesTubulinTubulin ModulatorsApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructurePolymerizationStructure-Activity RelationshipAntineoplastic AgentsChalconefosbretabulinStilbenesTubulinTubulin Modulatorsanti‐angiogenic effectcombretastatin A4‐chalconescytotoxicityimmunofluorescenceMitoSOX

Identifiers

PMID42647402
PMCPMC13513953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.